MIF and bronchopulmonary dysplasia: The partial improvement in alveolar architecture in the MIFTG-BPD model treated with MIF098 is probably due to the fact that the action of excess MIF occurs unabated after embryonic (E) day 14 (when the lung MIFTG is activated within the Type II alveolar epithelium) and the antagonist was administered only after PN1.